IL-PROJECT44
17.10.2018 09:02:30 CEST | Business Wire | Press release
project44 (p44) and Gatehouse Logistics jointly announced today that they have entered into an exclusive, multinational agreement which will provide secure and authorized access to the largest visibility network across North America and Europe. Ultimately, accelerating the ability for both technology providers to deliver visibility solutions across multiple transportation modes and geographies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005211/en/
End-to-end supply chain visibility is critical for complex global organizations looking to monitor global operations, increase efficiencies and improve the overall customer experience. This first of its kind multinational partnership provides visibility into key transportation processes, ensuring global organizations can accurately see and proactively respond to all events in their supply chain at the “speed of thought.”
Gatehouse Logistics CEO Jesper Bennike commented that, “project44 and Gatehouse Logistics have been championing the importance of high-fidelity data for years. This collaboration aligns with both company’s core promise to deliver the most comprehensive global visibility engine powered only by secure, high-quality and real-time information.”
Since 1992, Gatehouse Logistics has been leading the way in securely sharing data across the supply chain, bringing with it much-needed visibility of inbound and outbound logistics. ghTrack is a GDPR compliant, neutral and hardware agnostic data sharing service enabling Gatehouse Logistics to build the largest network of telematics systems across Europe. Similarly, project44 has quickly become the leader in North American advanced visibility by building the largest and most inclusive network of capacity providers connected via ELD, telematics, direct API connections, app-less tracking, or smartphone applications.
With this partnership, customers of project44 and Gatehouse Logistics now have immediate and actionable access to a network of 175,000 multimodal carriers - comprised of 90,000 capacity providers in North America and 85,000 in Europe. Implementation processes have also been expedited to ensure fast and frictionless onboarding for all customers and rapid time-to-value.
“Visibility is the number one supply chain initiative. We’ve seen a record number of North American and European companies investing in real-time visibility platforms to be used either stand-alone or with a TMS, CRM, WMS or ERP,” said project44 founder and CEO Jett McCandless. “This partnership accelerates the speed at which manufacturers, retailers, ecommerce providers, distributors, freight forwarders, and 3PLs can successfully realize the benefits of end-to-end visibility by working with a single visibility provider for all shipments regardless of geographic location.”
To learn more about this exclusive partnership or schedule a demo, visit https://get.project44.com/ghl-partnership/ . Executive leaders from project44 and Gatehouse Logistics will be attending the 35th International Supply Chain Conference in Berlin (October 17-19, 2018) hosted by BVL. Editors attending the BVL Conference are invited to a reception in Gartenlounge II at 14:00 on October 17 for an exclusive briefing.
About project44:
project44 is the world’s leading advanced visibility platform for shippers and third-party logistics firms. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations are able to increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to over 175,000 carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Truckload, Rail, Intermodal, and Ocean. To learn more, visit www.project44.com .
About GateHouse Logistics A/S:
GateHouse Logistics is the brand owner of ghTrack, a completely neutral and independent cloud-based data sharing service that is leading the way business-critical data is securely shared across the entire supply chain. It is also the perfect foundation for emerging smart industries including IoT developments. ghTrack brings long-wanted, real-time end-to-end visibility to all stakeholders in the supply chain. It aggregates position and sensor data from all modes of transportation and presents them as one unified and logical data stream for simple integration into any business system. ghTrack is Europe’s most widely used, secure and GDPR compliant data sharing service. Visit www.ghTrack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005211/en/
Contact:
North American Media Contact: project44 Ally Lynch, VP Marketing Phone: 1-312-300-4899 Email: ally@project44.com or European Media Contact: GateHouse Logistics Mette Lilkær, Strategic Sales & Marketing Manager Landline: + 45 7020 1909. Mobile + 45 2920 2383 Email: mdl@gatehouse.dk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom